Skip to main content

Advertisement

SpringerLink
Log in

Cancer Genomics for Oncologists: Cancer Risk and Management of BRCA1 and BRCA2 Carriers

  • Cancer Genomics (K Snape and H Hanson, Section Editors)
  • Published:
Current Genetic Medicine Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The rise of routine integration of genetic testing into oncological pathways, through initiatives such as mainstream testing, is making it increasingly important for oncologists to understand more about the wider implications of inherited mutations in cancer susceptibility genes. This is vital to facilitate accurate information-giving by oncologists, taking informed consent for testing, and to ensure they are referring patients appropriately for risk reduction strategies such as screening. In this review, the most relevant information for oncologists discussing and consenting patients will be discussed.

Recent Findings

Kuchenbaecker et al. (JAMA 317(23):2402-2416, 2017) have provided updated risk estimates for BRCA1 and BRCA2 carriers, from a large meta-analysis of international cohorts. For those considering risk-reducing interventions, we have evidence now from the POSH study to suggest that those diagnosed < 40 years have a 12% risk of carrying a mutation, with no detrimental effect from undergoing risk-reducing surgery. The role of chemotherapy for BRCA carriers with breast cancer was further assessed in cohorts from The Netherlands, MSKCC and the GeparSixto studies, assessing both overall survival and breast cancer–specific survival. For those considering surgical intervention, Metcalfe et al. (JAMA oncology 1(3):306-313, 2015) reported a survival advantage in BRCA cancers diagnosed with breast cancer undergoing risk-reducing bilateral salpingo-oophorectomy (RRBSO). The use of ovarian screening for BRCA carriers continues to be investigated by Rosenthal et al. (J Clin Oncol 35(13):1411-1420, 2017), who reported phase II of the UK FOCSS study, looking at their CA-125 algorithm and trans-vaginal ultrasound scanning. Whilst there is still no reduction in mortality for ovarian cancer, the studies of PSA screening for prostate cancer in BRCA carriers look more promising from the IMPACT study. The role of inherited gene mutations in ovarian cancer susceptibility outside of BRCA and Lynch was assessed by Song et al. (J Clin Oncol 33(26):2901-2907, 2015) in two different studies, investigating the role of BRIP1, RAD51C, RAD51D, RAD51B, BARD1, PALB2 and NBN. They concluded a causative role can only be confirmed for RAD51C, RAD51D and BRIP1.

Summary

Work continues on identifying the best way to find and test patients with germline genetic mutations, and the best way to manage carriers. These studies provide updated information on risk and the screening and management of individuals carrying these mutations to ensure they receive optimal care stratified by genetic risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. • Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–84 This is one of the seminal phase 3 studies of maintenance in second-line treatment of ovarian cancer.

    Article  CAS  PubMed  Google Scholar 

  2. •• Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495–505 This is the practice-changing first publication showing benefit from PARP inhibitor maintenance in the first-line treatment of BRCA-mutated ovarian cancer.

    Article  CAS  PubMed  Google Scholar 

  3. • Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive Recurrent Ovarian Cancer. N Engl J Med. 2016;375(22):2154–2164 This is one of the seminal phase 3 studies of maintenance in second-line treatment of ovarian cancer.

  4. • Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949–61 This is one of the seminal phase 3 studies of maintenance in second-line treatment of ovarian cancer.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. • Litton JK, Rugo HS, Ettl J, Hurvitz SA, Goncalves A, Lee KH, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753–63 This is one of the first papers demonstrating benefit from a PARP inhibitor in BRCA carriers with metastatic breast cancer.

    Article  CAS  PubMed  Google Scholar 

  6. • Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–33 This is the first phase 3 study demonstrating benefit from a PARP inhibitor in BRCA mutated ovarian cancer with metastatic breast cancer.

    Article  CAS  PubMed  Google Scholar 

  7. Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697–708.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Alsop K, Fereday S, Meldrum C, Defazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol : Off J Am Soc Clin Oncol. 2012;30:2654–63.

    Article  CAS  Google Scholar 

  9. Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet. 1997;60(3):505–14.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomark Prev. 2012;21(1):134–47.

    Article  CAS  Google Scholar 

  11. •• Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018;19(2):169–80 This provides evidence of overall outcome with conventional treatment for young woman with breast cancer, both those with and without BRCA mutations and also demonstrates a high rate of mutations in those diagnosed < 40 years.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Couch FJ, Farid LM, DeShano ML, Tavtigian SV, Calzone K, Campeau L, et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet. 1996;13(1):123–5.

    Article  CAS  PubMed  Google Scholar 

  13. Robertson L, Hanson H, Seal S, Warren-Perry M, Hughes D, Howell I, et al. BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer. 2012;106(6):1234–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. •• Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402–16 This provides updated risks for BRCA carriers using more modern cohorts, for unilateral breast cancer, bilateral breast cancer and ovarian cancer.

    Article  CAS  PubMed  Google Scholar 

  15. • Schmidt MK, van den Broek AJ, Tollenaar RA, Smit VT, Westenend PJ, Brinkhuis M, et al. Breast cancer survival of BRCA1/BRCA2 mutation carriers in a hospital-based cohort of young women. J Natl Cancer Inst. 2017;109(8). https://doi.org/10.1093/jnci/djw329. This paper provides evidence for the improved survival of breast cancer patients with a BRCA mutation–given chemotherapy.

  16. Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, Cybulski C, et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2009;115(2):359–63.

    Article  CAS  PubMed  Google Scholar 

  17. von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15(7):747–56.

    Article  CAS  Google Scholar 

  18. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol : Off J Am Soc Clin Oncol. 2015;33(1):13–21.

    Article  CAS  Google Scholar 

  19. • Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–21 This paper shows the benefit of the Oncotype DX in determining which patients with ER-positive breast cancer are most likely to require chemotherapy.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. • Shah PD, Patil S, Dickler MN, Offit K, Hudis CA, Robson ME. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status. Cancer. 2016;122(8):1178–84 This paper shows the differential risk of those with ER-positive breast cancer and a BRCA mutation by Oncotype DX, suggesting BRCA carriers have inherently higher risk disease than those without a mutation.

    Article  CAS  PubMed  Google Scholar 

  21. • Kuchenbaecker KB, McGuffog L, Barrowdale D, Lee A, Soucy P, Dennis J, et al. Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2017;109(7). https://doi.org/10.1093/jnci/djw302. This study looked at the role of polygenic risk scores in providing more specific risk assessments to those who carry a BRCA mutation.

  22. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol : Off J Am Soc Clin Oncol. 2005;23(30):7491–6.

    Article  Google Scholar 

  24. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346(21):1609–15.

    Article  PubMed  Google Scholar 

  25. Metcalfe K, Lynch HT, Foulkes WD, Tung N, Kim-Sing C, Olopade OI, et al. Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers. JAMA oncology. 2015;1(3):306–13.

    Article  PubMed  Google Scholar 

  26. • Rosenthal AN, Fraser LSM, Philpott S, Manchanda R, Burnell M, Badman P, et al. Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom Familial Ovarian Cancer Screening Study. J Clin Oncol: Off J Am Soc Clin Oncol. 2017;35(13):1411–20 This reports on the phase II findings of the UK FOCSS study showed no mortality benefit from ovarian screening in those with a BRCA mutation.

    Article  Google Scholar 

  27. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–34.

    Article  CAS  PubMed  Google Scholar 

  28. Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol. 2017;147(2):267–75.

    Article  CAS  PubMed  Google Scholar 

  29. Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol. 2014;66:489–99.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Mikropoulos C, Selkirk CGH, Saya S, Bancroft E, Vertosick E, Dadaev T, et al. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. Br J Cancer. 2018;118(2):266–76.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Bonadona V, Bonaiti B, Olschwang S, Grandjouan S, Huiart L, Longy M, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305(22):2304–10.

    Article  CAS  PubMed  Google Scholar 

  32. Engel C, Loeffler M, Steinke V, Rahner N, Holinski-Feder E, Dietmaier W, et al. Risks of less common cancers in proven mutation carriers with Lynch syndrome. J Clin Oncol. 2012;30(35):4409–15.

  33. Ketabi Z, Bartuma K, Bernstein I, Malander S, Gronberg H, Bjorck E, et al. Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors. Gynecol Oncol. 2011;121(3):462–5.

    Article  PubMed  Google Scholar 

  34. Rafnar T, Gudbjartsson DF, Sulem P, Jonasdottir A, Sigurdsson A, Jonasdottir A, et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet. 2011;43(11):1104–7.

    Article  CAS  PubMed  Google Scholar 

  35. Loveday C, Turnbull C, Ruark E, Xicola RM, Ramsay E, Hughes D, et al. Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet. 2012;44(5):475–6 author reply 6.

    Article  CAS  PubMed  Google Scholar 

  36. Pelttari LM, Heikkinen T, Thompson D, Kallioniemi A, Schleutker J, Holli K, et al. RAD51C is a susceptibility gene for ovarian cancer. Hum Mol Genet. 2011;20(16):3278–88.

    Article  CAS  PubMed  Google Scholar 

  37. Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet. 2011;43(9):879–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Song H, Dicks E, Ramus SJ, Tyrer JP, Intermaggio MP, Hayward J, et al. Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. J Clin Oncol: Off J Am Soc Clin Oncol. 2015;33(26):2901–7.

    Article  CAS  Google Scholar 

  39. Ramus SJ, Song H, Dicks E, Tyrer JP, Rosenthal AN, Intermaggio MP, et al. Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. J Natl Cancer Inst. 2015;107(11). https://doi.org/10.1093/jnci/djv214.

Download references

Author information

Authors and Affiliations

  1. Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK

    Angela George

  2. The Institute of Cancer Research, Cotswold Road, London, SM2 5NG, UK

    Angela George

  3. Gynae Oncology Unit and Cancer Genetics Unit, The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, 203 Fulham Road, London, SW3 6JJ, UK

    Angela George

Authors
  1. Angela George
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angela George.

Ethics declarations

Conflict of Interest

Angela George declares no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Cancer Genomics

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

George, A. Cancer Genomics for Oncologists: Cancer Risk and Management of BRCA1 and BRCA2 Carriers. Curr Genet Med Rep 7, 116–123 (2019). https://doi.org/10.1007/s40142-019-00167-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40142-019-00167-6

Keywords

Search

Navigation